Allarity Therapeutics, Inc.

ALLR Nasdaq SEC CIK 1860657
Follow Allarity Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $5K
Net income −$6.2M −121% vs same quarter last year
EPS, diluted −$0.39 −105.3% vs same quarter last year
Operating cash flow −$2.9M +15.6% vs same quarter last year
Revenue by quarter
$0
$0
$0
$320K
$25K
$0
$5K
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$11.2M
FY24−$24.5M
FY23−$11.9M
FY22−$16.1M
FY21−$26.6M
FY20−$6.6M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$14.8M
FY24−$17.7M
FY23−$12.7M
FY22−$16.8M
FY21-
FY20−$7.3M
FY19-